Table 5.
Autoinjector preferences from participants who had previously administered injections with an alternative autoinjector
| Respondents, n (%) | Formative study | Summative study | Total of formative and summative studies | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Abatacept autoinjector preference | Competitor autoinjector preference | Test preference of abatacept autoinjectora | Abatacept autoinjector preference | Competitor autoinjector preference | Test preference of abatacept autoinjectora | Abatacept autoinjector preference | Competitor autoinjector preference | Test preference of abatacept autoinjectora | |
| Patients | 12 (100) | 0 (0.0) | (73.54, 100.00); P = 0.00049 | 18 (78.3) | 5 (21.7) | (56.30, 92.54); P = 0.01062 | 30 (85.7) | 5 (14.3) | (69.74, 95.19); P = 0.00002 |
| Caregivers | 5 (100) | 0 (0.0) | (47.82, 100.00); P = 0.06250 | 11 (78.6) | 3 (21.4) | (49.20, 95.34); P = 0.05737 | 16 (84.2) | 3 (15.8) | (60.42, 96.62); P = 0.00443 |
| HCPs | 7 (87.5) | 1 (12.5) | (47.35, 99.68); P = 0.07031 | 12 (100) | 0 (0.0) | (73.54, 100.00); P = 0.00049 | 19 (95.0) | 1 (5.0) | (75.13, 99.87); P = 0.00004 |
aDisplayed as (95% confidence interval); P value